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Abstract
Dengue is a major public health problem in tropical and subtropical regions; however, under-reporting of cases to national
surveillance systems hinders accurate knowledge of disease burden and costs. Laboratory-confirmed dengue cases
identified through the Nicaraguan Pediatric Dengue Cohort Study (PDCS) were compared to those reported from other
health facilities in Managua to the National Epidemiologic Surveillance (NES) program of the Nicaraguan Ministry of Health.
Compared to reporting among similar pediatric populations in Managua, the PDCS identified 14 to 28 (average 21.3) times
more dengue cases each year per 100,000 persons than were reported to the NES. Applying these annual expansion factors
to national-level data, we estimate that the incidence of confirmed pediatric dengue throughout Nicaragua ranged from
300 to 1000 cases per 100,000 persons. We have estimated a much higher incidence of dengue than reported by the
Ministry of Health. A country-specific expansion factor for dengue that allows for a more accurate estimate of incidence may
aid governments and other institutions calculating disease burden, costs, resource needs for prevention and treatment, and
the economic benefits of drug and vaccine development.
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Introduction
Dengue is a mosquito-borne illness that is a major public health
problem in tropical and subtropical regions, causing millions of
cases annually [1]. However, under-reporting of dengue cases to
national surveillance systems hinders accurate local, regional and
global calculations of disease burden and costs, which in turn
impact appropriate resource allocation and availability of reliable
data for vaccine and drug development. Under-reporting has been
attributed to a range of factors, including misdiagnosis, limited
laboratory capabilities, poor application of the World Health
Organization (WHO) case definition, and limitations of national
reporting systems, among others [2,3]. Furthermore, scarce data
on inapparent dengue virus (DENV) infections limits estimates of
risk for more severe secondary infections. To address the lack of a
country-specific estimate of disease burden based on surveillance
data, we calculated the difference in dengue case capture rates
between a pediatric dengue cohort study (PDCS) and the Ministry
of Health dengue surveillance program (‘‘expansion factor’’) in
Managua, Nicaragua, which can be applied to national statistics
for more accurate estimations of dengue burden.
Materials and Methods
The PDCS is a community-based, prospective cohort study that
was initiated in 2004 in a low-to-middle-income district of
Managua and is based in a municipal clinic, the Health Center
So ´crates Flores Vivas (HCSFV), which is the principal source of
health care for the district’s population. The study captured
possible dengue cases through ‘‘enhanced’’ passive surveillance by
study physicians and nurses at the HCSFV and periodic home
visits for follow-up and monitoring of study compliance [4].
Cohort participants, initially aged 2–9 years old in 2004, were
followed closely for all illnesses, and children who presented with
fever were screened for signs and symptoms of dengue. Those who
met WHO criteria for suspected dengue (acute febrile illness with
two or more of the following symptoms or signs: headache, retro-
orbital pain, myalgia, arthralgia, rash, hemorrhagic manifesta-
tions, leukopenia, or platelets #150,000/mm
3) as well as those
with undifferentiated fever were evaluated for acute DENV
infection. A dengue case was considered laboratory-confirmed
when 1) DENV was isolated, 2) DENV RNA was demonstrated by
reverse-transcriptase polymerase chain reaction (RT-PCR), 3)
seroconversion was observed with paired acute and convalescent
phase sera by IgM capture ELISA or Inhibition ELISA [5,6], or 4)
a $4-fold increase in antibody titer in paired acute and
convalescent sera was observed by Inhibition ELISA [7]. Overall,
118 (74%) of the confirmed DENV infections in the PDCS
complied with the WHO case definition (15 (88%), 44 (68%), 8
(62%), and 51 (80%) in years 2004–5, 2005–6, 2006–7, 2008–9,
respectively), while 41 (26%) had undifferentiated fever (2 (12%),
21 (32%), 5 (38%), and 13 (20%) in years 2004–5, 2005–6, 2006–
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cases in the cohort in 2004–5, 2005–6, 2006–7, 2007–8,
respectively, all of which were compliant with the WHO case
definition.
Inapparent DENV infections, presented here separately from
symptomatic cases, were identified through serological testing of
paired annual blood draws from healthy subjects, which were
collected every year in July. Specifically, children with paired
annual serum samples demonstrating seroconversion or $4-fold
increase in DENV-specific antibody titer, but who had not
presented to the HCSFV with acute DENV illness, were
considered to have experienced inapparent DENV infections
[4,8]. All confirmatory testing was conducted at the National
Virology Laboratory (NVL) of the Nicaraguan Ministry of Health,
the same laboratory responsible for confirmatory testing of
routine, non-PDCS suspected dengue cases in Managua (see
below). This study was approved by the Institutional Review
Boards of the Nicaraguan Ministry of Health; the study hospital,
Hospital Infantil Manuel de Jesu ´s Rivera (HIMJR); the University
of California, Berkeley; and the International Vaccine Institute.
Parents or legal guardians of all subjects provided written informed
consent, and subjects over 5 years of age gave verbal assent.
Between 2004 and 2008, a total of 4,742 children participated
in the PDCS, with a yearly active cohort of 3,693-3,795 children
with equal distribution by gender, age and neighborhood.
Compliance and participation were consistently high [4]. Over
90% of participants sought medical care at the HCSFV at least
once during the study period, and loss to follow-up – primarily due
to moving outside of the study district – was low (4.3–7.1%
annually). Possible dengue cases presented early to the HCSFV
(94% presenting within the first 72 hours since symptom onset)
and 94% provided a convalescent sample [4].
The National Epidemiologic Surveillance program (NES)
collects information on suspected and confirmed dengue cases at
the primary and secondary care level. Physicians in both the public
and private sectors are required to report suspected cases meeting
WHO criteria (see definition above) via a standardized MOH
reportable disease form and to send blood samples ($5 days since
onset of fever) to the NVL at the MOH for testing. All febrile cases
presenting at public facilities are reported, but only for those
meeting the WHO definition is a suspected dengue report filled
out and sample collected. Approximately 60% of suspected dengue
cases in Managua have blood samples sent to the NVL (A.
Balmaseda, unpublished data). A suspected case is considered
positive (referred to here as a ‘‘confirmed’’ case) when the sample
tests positive for DENV-specific IgM antibodies via IgM capture
ELISA or, in rare cases, if the sample is obtained during the first 5
days after symptom onset and DENV RNA is detected.
Data on confirmed and suspected dengue cases by epidemiologic
week among children 2–14 years old (and children 1–14 years old in
2004–5, before the NES began reporting 1 year-olds separately)
wereobtained from the NES for the years 2004–8, correspondingto
the first four years of the PDCS. NES data include both confirmed
and suspected cases reported by primary and secondary health
facilities in Managua (primarily public, as private facilities do not
comply as frequently with reporting guidelines), and are presented
here by year, age group, and the health center corresponding to the
district of residence of the child. The population of 1–14 year-olds
(2004) and 2–14 year-olds (2005–8) in each health center’s district
was also obtained from the NES. These data were used to calculate
incidence of confirmed dengue per 100,000 persons corresponding
to each health center’s district and overall in Managua. The
expansion factor for confirmed cases was calculated by dividing the
annual incidence of laboratory-confirmed symptomatic dengue
among PDCS participants by the annual incidence of laboratory-
confirmed dengue in Managua according to NES statistics. In
addition, a sub-analysis was performed to calculate expansion
factors using only data from 2–9 year-old children in both the
PDCS and Managua (NES) in 2005–8 in order to compare the
results with expansion factors calculated using the complete data
sets, which could not be precisely age-matched (age-disaggregated
data is not available from the NES: in 2004, NES dengue case
reports are aggregated into 1–14 year-old age groups, and in 2005–
8, into 1, 2–4, 5–9, and 10–14 year-old age groups). We also
calculated an expansion factor for suspected dengue cases by
dividing the annual incidence of suspected dengue cases in the
PDCS meeting WHO criteria by the annual incidence of suspected
dengue cases according to NES statistics. In addition, we calculated
the ratio of inapparent DENV infections (defined above) to
symptomatic dengue cases in the cohort. Annual incidence and
expansion factors were calculated in relation to the annual dengue
season, beginning in July of each year.
Results
In the PDCS cohort, between 13 and 65 confirmed cases were
recorded annually (Table 1), and between 0 and 51 confirmed cases
were reported to the NES in individual health districts (data not
shown). This translates to incidence of dengue ranging from 343 to
1,759 cases per 100,000 persons in the cohort study, as compared to
21 to 77 cases per 100,000 persons across all Managua’s health
centers (Table 1). The HCSFV, where the cohort study is based,
reported greater numbers of confirmed and suspected dengue cases
among its non-PDCS patients to NES than most other health
centers (51 to 206 cases per 100,000, data not shown), though still
only a fraction of the incidence observed in the cohort (Figure 1).
The expansion factor ranged from 14 to 28 dengue cases in the
cohort study for every confirmed case reported by the NES. Thus,
despite year-to-year variation in the numbers of dengue cases, the
cohort study consistently identified approximately 15- to 30-fold
(average 21.3) more cases than were reported in Managua via
Author Summary
National public health and epidemiology programs are
often tasked with tracking certain infectious diseases, but
many barriers lead to under-reporting. In tropical and
subtropical countries where dengue fever is endemic,
under-reporting may be due to misdiagnosis, limitations of
the WHO case classification, and lack of laboratory
infrastructure or resources, among other issues. In
Nicaragua’s capital, Managua, we compared the number
of dengue cases identified in a cohort study of 2- to 12-
year-old children in one health center to the number of
pediatric cases reported from all other municipal health
centers in Managua to the National Epidemiologic
Surveillance (NES) program. In the years 2004–2008,
between 13 and 65 dengue cases were identified in the
cohort (approximately 3,700 participants), and between 0
and 51 cases were reported by individual health centers in
Managua. When the incidence per 100,000 people was
calculated and compared, an average of 21 times more
dengue cases were identified in the cohort study
compared to the number reported to NES. Application of
such an expansion factor may help governments and other
health institutions to estimate the actual number of
dengue cases in a population and therefore better allocate
resources for prevention, treatment, and drug and vaccine
development.
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national-level data, the estimatedincidenceof laboratory-confirmed
dengue throughout Nicaragua ranged from approximately 300 to
1,000 cases per 100,000 persons. In a sub-analysis using only 2–9
year-olds in the PDCS and Managua NES data sets in 2005–8, we
calculated expansion factors of 26, 19 and 21 – very similar to the
numbers (24, 14 and 22) obtained using the full data sets in 2005–8.
Expansion factors were also calculated based on PDCS and NES
suspected dengue cases, yielding an average of 21 (range 16–28)
times more suspected cases per 100,000 persons in the PDCS
compared to those reported by NES throughout Managua.
The ratio of inapparent to symptomatic DENV infection in
PDCS participants also varied year-to-year [8] from 16 in 2004–5
and 2006–7, to 5 and 3 in 2005–6 and 2007–8, respectively
(Table 1). Combining the ratio of inapparent to symptomatic
DENV infection with the calculated expansion factor each year,
we estimate 68–347 (average 193) inapparent DENV infections for
every one symptomatic DENV infection reported to the NES.
During the four years analyzed, 42% of inapparent DENV
infections in the PDCS were primary, and thus at greater risk of
more severe disease in a second DENV infection.
Discussion
In this study, we have shown much higher incidence of
symptomatic DENV infection in a pediatric cohort study than is
reported to the national surveillance system from comparable
urban public health centers. Annual expansion factor calculations
indicate that up to 28 times more symptomatic DENV infections
may occur than are reported to the NES, and under-reporting
may be even greater among older age groups. This expansion
factor, albeit a rough approximation, provides an estimate of the
actual impact of dengue on this urban Latin American population,
which may be of great use to governments and other institutions
involved in dengue prevention and research. Furthermore,
estimates of inapparent DENV infections and their immune status
(primary vs. secondary) such as we provide here, especially when
coupled with information about circulating DENV serotypes each
year, may be useful for understanding the level of protective
immunity in the population as well as help assess population risk
for more severe dengue, since the single greatest risk factor for
severe disease is a previous infection with a distinct DENV
serotype [9]. This data also illustrates that total DENV
transmission is distinct from transmission that can be observed
clinically or reported through national surveillance systems.
This was not a classic capture-recapture study, but rather an
ecological study comparing incidence rates in a cohort to national
surveillance rates in the surrounding urban areas. The application
and calculation of an expansion factor based on PDCS data has
several limitations. The expansion factor cannot be applied to
adult populations as only children, who are most affected by
dengue in the study area, were included in the study. Limitations
Table 1. Incidence of confirmed and suspected dengue cases and expansion factors.
2004–5 2005–6 2006–7 2007–8
Laboratory-confirmed Symptomatic Dengue Cases
PDCS dengue cases (n)
1 17 65 13 64
PDCS participants (n)
1,2 3,721 3,695 3,795 3,693
PDCS dengue incidence per 100,000 persons 457 1,759 343 1,733
NES dengue cases reported in Managua health centers (n)
3 99 252 102 278
Population of Managua in health center districts, excluding PDCS (n)
3 464,733 398,079 405,378 358,824
Managua NES dengue incidence per 100,000 persons 21 63 25 77
Expansion factor based on confirmed cases
4 21 28 14 22
Suspected Dengue Cases
PDCS suspected dengue cases (n)
5 210 335 195 233
PDCS incidence of suspected dengue per 100,000 persons 5644 9066 5138 6309
Managua NES suspected dengue cases
6 1384 1279 1116 1391
Managua NES incidence of suspected dengue per 100,000 persons 298 321 275 388
Expansion factor based on suspected cases
7 19 28 19 16
Symptomatic and Inapparent DENV Infections in PDCS Cohort
Symptomatic DENV infections
8 17 64 11 60
Inapparent DENV infections 276 318 176 182
Ratio of inapparent to symptomatic DENV infections 16 5 16 3
Inapparent DENV infections for each symptomatic case reported by NES 347 138 218 68
12–9 years old in 2004–5, 2–10 in 2005–6, 2–11 in 2006–7 and 2–12 in 2007–9 (the cohort aged by one year each year).
2Includes all subjects active in the cohort for at least half of the study year, whether or not an annual sample was taken at the end of the year.
31–14 years old in 2004–5 and 2–14 years old for all other years.
4Expansion factor = PDCS incidence of confirmed dengue/Managua NES incidence of confirmed dengue.
5Includes suspected cases that met WHO criteria (see Materials and Methods); cases of undifferentiated fever, which account for 25% of laboratory-confirmed dengue
cases in the PDCS, are not included in this figure.
6Suspected dengue cases are defined by the NES according to WHO criteria (see Materials and Methods).
7Expansion factor = PDCS incidence of suspected dengue/Managua NES incidence of suspected dengue.
8Includes symptomatic cases identified only among those subjects who completed the study year and for which paired annual samples were available for determination
of inapparent infection (n=152, of 159 symptomatic dengue cases among cohort participants identified in 2004–8).
doi:10.1371/journal.pntd.0000633.t001
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the same age groups as PDCS participants (e.g. 2–9 in 2004–5, 2–
10 in 2005–6, etc); the larger NES population used (through 14
years old) may have led to slightly lower calculated expansion
factors. However, in a sub-analysis restricted in both the PDCS
and NES data to only 2–9 year-old children in 2005–8, expansion
factors were found to be very similar to the numbers obtained with
the full data set in 2005–6 and 2007–8 (26 vs. 28 and 21 vs. 22,
respectively). The slightly higher expansion factor in 2006–7 for 2–
9 year old children only (19 vs. 14) is due to the higher incidence
that year in 10–14 year-olds in Managua; this was not apparent in
the older PDCS participants, which included only 10 and 11 year-
old children that year (Table 2). Additionally, the HCSFV district,
which borders Lake Managua, may have higher dengue rates than
other health centers, as there was more reported dengue among
the non-study population of the HCSFV. However, another
plausible explanation is that these higher numbers are due to the
impact of the PDCS study protocol and increased awareness of
dengue among both non-PDCS medical staff at the HCSFV and
in the general population of the HCSFV catchment area. A
greater expansion factor for pediatric dengue may be estimated in
our study due to the inclusion of undifferentiated febrile illnesses
that do not fit the traditional WHO definition, which account for
approximately 25% of symptomatic cases identified in the cohort
[8]. However, we also calculated an expansion factor based on
suspected dengue cases (which only reflect the WHO criteria) in
the PDCS compared to suspected cases in Managua health
centers, and obtained very similar results as those calculated using
only confirmed cases. While we were unable to restrict the
estimates of national incidence to only urban areas due to
limitations of the NES reporting system, since over 56% of
Nicaragua is urban, using the entire Nicaraguan population could
Figure 1. Reported laboratory-confirmed dengue cases among children in Managua health centers and in the PDCS, 2004–8.
Laboratory-confirmed dengue cases among 1–14 year-old children in 2004–5 and 2–14 year-old children in 2005–8 reported in Managua health
centers by the NES and in 2–12 year-old children meeting the WHO case definition in the PDCS 2004–8.
doi:10.1371/journal.pntd.0000633.g001
Table 2. Age-stratified incidence and expansion factors
1.
2005–6 2006–7 2007–8
PDCS Incidence of Confirmed Dengue
2
Entire cohort (2–12 years old) 1,759 343 1,733
2–4 years old 1,469 412 1,173
5–9 years old 1,913 376 1,610
10–12 years old 1,749 143 2,734
Managua NES Incidence of Confirmed
Dengue
2
2–14 years old 63 25 77
2–4 years old 55 18 52
5–9 years old 74 21 83
10–14 years old
3 57 33 87
Expansion factors
4
2–14 years old 28 14 22
2–4 years old 27 23 22
5–9 years old 26 18 19
10–14 years old 30 4 31
1NES data by age groups was not available for 2004–5; thus, analysis has been
restricted to 2005–8.
2Per 100,000 inhabitants.
3Disaggregated data for 10, 11 and 12 year-old children is not available from
the NES and thus the 10–14 year old age group has been used to calculate
incidence and expansion factors.
4Expansion factor = PDCS age-stratified incidence/Managua NES age-stratefied
incidence.
doi:10.1371/journal.pntd.0000633.t002
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our calculated expansion factors (,20-fold) are an order of
magnitude greater than this potential correction factor; thus, we
believe our overall estimates and conclusions to be valid and
useful.
Despite these limitations, our expansion factors falls in the same
range as the only published expansion factors for ambulatory
dengue. Meltzer et al. [10] calculated that 10 and 27 times more
DENV cases occur in Puerto Rico than are reported in pediatric
and adult populations, respectively. It is to be expected that
expansion factors may vary somewhat in different countries with
distinct surveillance programs, health care systems, and degrees of
under-reporting. More sophisticated analysis is needed to calculate
more precise expansion factors, for instance by controlling for
socioeconomic and other district-level factors, and additional data
is needed in order to calculate similar expansion factors for adult
populations.
Nonetheless, an expansion factor such as we present here should
allow for more accurate estimations of dengue burden and
economic costs. Such estimates can benefit government surveil-
lance programs, aid in allocation of resources to medical care and
prevention, and facilitate calculation of the economic benefits of
developing vaccines and drugs against dengue.
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